MedTrace Logo

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test

NCT04221906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-11-18

No results posted yet for this study

Summary

This study is being conducted to evaluate the safety of topical BOS-475 compared to topically applied comparator formulations and vehicle.

Conditions

  • Chronic Plaque Psoriasis

Interventions

DRUG

BOS-475

topical cream

DRUG

Active ingredient-free vehicle cream

topical cream

DRUG

Daivonex cream (calcipotriol 0.005%)

topical cream

DRUG

Betnesol-V cream (betamethasone 0.1%)

topical cream

Sponsors & Collaborators

  • Boston Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Xiaobing Qian, MD, PhD · Boston Pharmaceuticals, Vice President, Clinical Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2020-03-06
Completion
2020-03-06
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221906 on ClinicalTrials.gov